RESEARCH TRIANGLE PARK, N.C. — Drug development firm Icagen has hired Seth Hetherington, a former executive with Inhibitex, to be its senior vice president for clinical and regulator affairs.
Hetherington, an MD, was chief medical officer and vice president for clinical development at Inhibitex. Earlier in his career he worked for GlaxoSmithKline.
“Dr. Hetherington brings to Icagen an outstanding background in all phases of clinical drug development from Phase I clinical trials through product registration,” said P. Kay Wagoner, chief executive officer of Icagen. “His breadth of both clinical and regulatory experience provides him with an ideal background to lead our clinical development efforts.”
Icagen has under development a proposed treatment for sickle cell disease.